Background
==========

Epilepsy is a common and complex disease characterized by a predisposition to recurrent unprovoked seizures \[[@b1-medscimonit-21-861]\]. After treatment with anti-epileptic drugs (AEDs), most epileptic patients respond well to medications. However, about one-third of newly treated patients do not respond adequately to medications, because these patients exhibit drug resistance to AEDs \[[@b2-medscimonit-21-861]\]. P-glycoprotein (P-gp) was the first discovered human ABC (the ATP-binding cassette) transporter in drug-resistance ovarian cells several decades ago \[[@b3-medscimonit-21-861]\]. P-gp is the expression product of ABCB1 (the ATP-binding cassette, subfamily B, member 1 transporter gene), which is also known as MDR1 (multi-drug resistance gene 1). The ABCB1 gene is highly polymorphic and more than 50 variants reside in the coding region which can possibly cause altered function \[[@b4-medscimonit-21-861]\]. The C3435T polymorphism is one of the most common polymorphisms in the ABCB1 gene. Siddiqui et al. \[[@b5-medscimonit-21-861]\] first reported that among Caucasians, the C3435T single-nucleotide polymorphism (SNP) of ABCB1 was correlated with drug resistance in epilepsy. Following that study, more than 20 replication studies \[[@b6-medscimonit-21-861]--[@b27-medscimonit-21-861]\] were conducted to evaluate this hypothesis.

In 2010, Haerian et al. \[[@b28-medscimonit-21-861]\] performed a meta-analysis and did not find an association between ABCB1 polymorphism and drug resistance in epilepsy. In recent year, several large sample-size and well-designed studies related to this topic have been conducted \[[@b29-medscimonit-21-861]--[@b33-medscimonit-21-861]\]. However, the results remain contradictory. To clarify the association with ABCB1 gene C3435T polymorphism and drug resistance in epilepsy, we performed an updated meta-analysis to further explore the correlations between the ABCB1 C3435T polymorphism and drug resistance in epilepsy.

Material and Methods
====================

Literature screening
--------------------

We used the keywords "polymorphism", "multi-drug resistance gene 1", "C3435T", "epilepsy", "intractable epilepsy", "antiepileptic drugs", and "drug-resistant" to search the Cochrane Library, MEDLINE, EMBASE, PubMed, Science Direct database, China National Knowledge Infrastructure (CNKI) database, the China Biomedical Literature (CBM) database, the MedCH international medical abstract database, and Wanfang up to October 2014. These searches were supplemented by retrospective and manual searches of the literature by going to a library to read paper copies of scientific journals. The first report on the relationship between the ABCB1 C3435T polymorphism and drug resistance in epilepsy appeared in 2003, and the end date for the retrieval process was October 31, 2014.

Literature inclusion and exclusion criteria
-------------------------------------------

### Literature inclusion criteria

1\) Chinese or English publication that addressed the association of the ABCB1 C3435T polymorphism with drug resistance in epilepsy; 2) reported complete data, including the number of examined individuals in the drug-resistant group and the therapeutically effective group, the frequency of the CC, CT, and TT genotypes at the 3435 locus of the ABCB1 gene; 3) the study subjects were epileptic patients who were treated with AEDs.

### Exclusion criteria

Studies were excluded if: 1) they were duplicate publications from the same population and the same authors examined in another publication, in which case only the publication with the largest sample size was retained; or 2) they did not contain sufficient quantity or quality of data to analyze.

Data extraction
---------------

Data extraction was performed independently by 2 researchers (Li SX and Liu YY), and the extracted data were subsequently verified. The retrieved data included the author names, the date of publication, the nationality of the study population, and the allele and genotype frequency distributions. If genotype frequency distributions were expressed as percentages, then data were entered after converting these percentages into numbers of cases. If allele distributions were not provided, then these distributions were calculated from genotype distributions.

Statistical analysis
--------------------

Meta-analysis was performed using the RevMan 5.0 software. Cochran's Q test was used for the analysis of heterogeneity between the results of each study. When there was no heterogeneity between studies (I^2^\<50%), a fixed-effects model was used for the meta-analysis. When there was heterogeneity (I^2^\>50%), a random-effects model was used for the meta-analysis. The OR and 95% CI of each allele and genotype frequency were calculated for each study. The Hardy-Weinberg equilibrium of the control group was calculated. P\<0.05 was considered statistically significant. Sensitivity analysis was conducted using the individual exclusion method. The overall effects were re-assessed and compared with the overall effects prior to exclusion. Begg's test and Egger's test were applied to determine whether there was publication bias in the studies.

Results
=======

Search results and literature
-----------------------------

As shown in [Figure 1](#f1-medscimonit-21-861){ref-type="fig"}, a total of 189 articles were retrieved after first search in the Cochrane Library, MEDLINE, EMBASE, PubMed, Science Direct database, China National Knowledge Infrastructure (CNKI) database, the China Biomedical Literature (CBM) database, the MedCH international medical abstract database, and Wanfang up to October 2014. Finally, there were 28 articles including 30 independent case-control studies \[[@b6-medscimonit-21-861]--[@b27-medscimonit-21-861],[@b29-medscimonit-21-861]--[@b33-medscimonit-21-861]\] that fulfilled the inclusion criteria. The characteristics of each study are summarized in [Table 1](#t1-medscimonit-21-861){ref-type="table"}. These 30 studies involving 8604 subjects were ultimately analyzed in our meta-analysis. There were 17 studies carried out in Caucasian populations while the other 13 studies were performed in Asian populations. In the subgroup analysis, patients from Hong Kong, China were included in the Asian population, whereas patients from Australia and Scotland were included in the Caucasian population. Therefore, there were effectively a total of 13 studies examining Asian populations and a total of 17 studies that examined Caucasian populations ([Table 1](#t1-medscimonit-21-861){ref-type="table"}).

Meta-analysis results
---------------------

Analysis of the allele contrast model (C *vs.* T) for the overall population revealed that there was high heterogeneity among the included studies (I^2^=64%, P\<0.001); therefore, a random-effects model was used to pool the OR values for the frequency of the 3435C allele. The pooled OR value was 1.07 (95% CI: 0.95--1.19, P=0.26) in allele model and 1.05 (95% CI: 0.89--1.24, P=0.55) in genotype model, indicating that the 3435C allele was not significantly correlated with drug resistance in epilepsy ([Table 2](#t2-medscimonit-21-861){ref-type="table"}). Subgroup analyses were performed in accordance with the race of the study subjects There was significant heterogeneity among the studies examining Asian populations (I^2^=−76%, P\<0.001); therefore, a random-effects model was used to pool OR values, producing a pooled OR value of 1.03 (95% CI: 0.84--1.26, P=−0.77) in allele model and 0.90 (95% CI: 0.70--1.17, P=−0.43) in genotype model ([Table 2](#t2-medscimonit-21-861){ref-type="table"}). There was no heterogeneity among studies examining Caucasian populations (I^2^=42%, P=0.04); therefore a fixed-effects model was utilized to merge the OR values. We found in Caucasian populations there are significant differences between resistance group and control group in both allele model (C *vs.* T: OR=1.07; 95%CI: 0.95--1.19) and in genotype model (CC *vs.* CT+TT: OR=1.05; 95%CI: 0.89--1.24, P=0.55, [Table 2](#t2-medscimonit-21-861){ref-type="table"} and [Figure 2](#f2-medscimonit-21-861){ref-type="fig"}).

Quality analyses of the included studies
----------------------------------------

### Sensitivity analysis

We deleted 1 study from the overall pooled analysis each time to check the influence of the removed data set on the overall ORs. The pooled ORs and 95% CIs were not significantly altered when any part of the study was omitted, which indicated that this study exhibited relatively good stability.

### Analysis of publication bias

Funnel plot and Egger's test were performed to assess the publication bias of the literatures. Symmetrical funnel plots were obtained in the SNP tested in all of the models. Egger's test further confirmed the absence of publication bias in this meta-analysis (P\>0.05) ([Figure 3](#f3-medscimonit-21-861){ref-type="fig"}). Similarly, additional analyses of the studies included in the examined genetic models and subgroups revealed no significant publication bias, indicating that the study results were relatively creditable.

Discussion
==========

In the present study, we found that the C3435T polymorphism was associated with AEDs in Caucasian populations. This meta-analysis collected 28 publications addressing the relationship between the ABCB1 C3435T polymorphism and drug resistance in epilepsy. However, the results were contradictory. The C3435T polymorphism of ABCB1 gene was the first single-nucleotide polymorphism that was reported to be associated with drug resistance in epileptic patients \[[@b6-medscimonit-21-861]\]. In this report, the CC genotype of this polymorphism was found to be significantly higher in patients with drug-resistant epilepsy, whereas the TT genotype was significantly lower in the same group \[[@b6-medscimonit-21-861]\]. However, several studies failed to confirm the association between the C3435T polymorphism and drug-resistant epilepsy. In this meta-analysis, only 6 studies produced positive results \[[@b6-medscimonit-21-861]--[@b11-medscimonit-21-861]\], and in the remaining 24 studies no correlation was found between the C3435T polymorphism and drug resistance in epilepsy. Meta-analysis results showed no statistically significant correlation between the ABCB1 C3435T polymorphism and drug resistance in epilepsy in analyses of either the allele model or genetic model in the total population. Furthermore, subgroup analyses organized in accordance with subjects' racial groups (Asian or Caucasian) revealed positive correlations between this polymorphism and drug resistance in epilepsy in Caucasian populations but not in Asian populations.

In the present study, we found significant heterogeneity among each study, primarily because of 3 factors. 1) The specific pathogenic gene *loci* that cause differences in ABCB1 function remain unclear; and 2) various included studies involved different uses of AEDs. For instance, certain included studies involved AED monotherapies, whereas others included investigations with combination therapies. Among the currently known AEDs, phenytoin, levetiracetam, lamotrigine, and phenobarbital are all transported by P-gp in the human body. In contrast, valproic acid is not transported by P-gp; thus, if valproic acid was administered to many of the examined patients, it may be difficult to accurately determine whether the ABCB1 C3435T polymorphism is truly correlated with drug resistance in epilepsy. 3) Currently, there is no universally accepted definition of drug resistance in epilepsy. Siddiqui et al. \[[@b6-medscimonit-21-861]\] defined drug resistance in epilepsy as the occurrence of at least 4 seizures during the year prior to a subject's enrollment despite the use of at least 3 appropriately selected AEDs at these drugs' maximum tolerated doses. Because different researchers used different criteria, certain patients who would have been classified into the therapeutically effective group by the aforementioned definition were instead classified into the drug resistance group in certain studies. This difference in patient categorization is also an important reason for the different results of various studies.

Conclusions
===========

The current meta-analysis only confirmed the existence of significant correlations between this polymorphism and drug resistance in epilepsy in Caucasian populations. However, our results should be verified by a case-control study with larger sample size.
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###### 

The characteristics of included studies.

  Authors               Publication year   Country     Number of Subjects   NR    R     NR    R                                        
  --------------------- ------------------ ----------- -------------------- ----- ----- ----- ----- ----- ----- ---- ----- ----- ----- -----
  Alpman et al.         2010               Turkey      39                   92    6     20    12    26    37    24   32    44    89    85
  Haerian et al.        2011               Asian       323                  362   109   158   56    110   180   72   376   270   400   324
  Szoeke et al.         2009^a^            Australia   64                   148   21    27    16    34    67    47   69    59    135   161
  Szoeke et al.         2009^b^            Scotland    133                  152   20    69    44    34    72    46   109   157   140   164
  Szoeke et al.         2009^c^            China       11                   34    1     8     2     13    20    1    10    12    46    22
  Tan et al.            2004               Australia   401                  208   75    193   133   37    115   56   343   459   189   227
  Chen L et al.         2007               China       50                   164   15    25    10    63    79    22   55    45    205   123
  Di Q et al.           2011               China       91                   79    44    37    10    32    30    17   125   57    94    64
  Dong et al.           2011               China       157                  193   64    75    18    82    83    28   203   111   247   139
  Hung et al.           2007               China       114                  213   40    55    19    39    107   67   135   93    185   241
  Kwan et al.           2007               China       221                  297   80    104   37    114   161   22   264   178   389   205
  Ufer et al.           2009               Germany     188                  103   44    85    59    20    46    37   173   203   86    120
  Grover et al.         2010               India       87                   125   13    44    30    14    55    56   70    104   83    167
  Kumaril et al.        2011               India       125                  260   12    67    46    42    120   98   91    159   204   316
  Takhan et al.         2009               India       94                   231   9     52    33    38    104   89   70    118   180   282
  Vahab et al.          2009               India       113                  54    3     61    49    3     8     43   67    159   14    94
  Sayyah et al.         2011               Iran        132                  200   34    55    43    32    80    88   123   141   144   256
  Shahwan et al.        2007               Ireland     122                  233   20    64    38    37    119   77   104   140   193   273
  Seo et al.            2006               Japan       126                  84    34    58    34    36    34    14   126   126   106   62
  Kim et al.            2009               Korea       198                  193   73    97    28    81    90    22   243   153   252   134
  Emich-Widera et al.   2013               Poland      60                   25    9     33    18    1     16    8    51    69    18    32
  Emich-Widera et al.   2014               Poland      193                  135   19    114   60    21    82    32   152   234   124   146
  Sills et al.          2005               Scotland    230                  170   41    112   77    32    82    56   194   266   146   194
  Sanchez et al.        2010               Spain       111                  178   40    49    22    52    81    45   129   93    185   171
  Dericiogl et al.      2008               Turkey      89                   100   26    34    29    25    49    26   86    92    99    101
  Ozgon et al.          2008               Turkey      44                   53    13    26    5     16    29    8    52    36    61    45
  Saygi et al.          2014               Turkey      59                   60    19    26    14    12    30    18   64    54    54    66
  Seven et al.          2014               Turkey      69                   83    17    30    22    22    38    23   64    74    82    84
  Siddiqui et al.       2003               UK          200                  115   55    106   39    18    63    34   216   184   99    131
  Soranzo et al.        2004               UK          280                  136   73    145   62    20    80    36   291   269   120   152

NR -- anti-epileptic drug no response (case group); R -- effective group (control group). a, b, and c represent independent studies from the same article.

###### 

Meta-Analysis of C3435T polymorphism of the ABCB1 gene and drug resistance in epilepsy.

  Genetic model       Sample size   Test of association   Test for heterogeneity                                 
  ------------------- ------------- --------------------- ------------------------ ------------ ------ --------- -----
  Total                                                                                                          
   CC *vs.* (CT+TT)   4124          4480                  1.05                     0.89--1.24   0.55   0.0003    54%
   C *vs.* T          8246          8950                  1.07                     0.95--1.19   0.26   \<0.001   64%
  Caucasian                                                                                                      
   CC *vs.* (CT+TT)   2414          2191                  1.20                     1.04--1.40   0.01   0.04      42%
   C *vs.* T          4826          4372                  1.09                     1.00--1.18   0.05   0.02      48%
  Asian                                                                                                          
   CC *vs.* (CT+TT)   1710          2289                  0.90                     0.70--1.17   0.43   0.002     61%
   C *vs.* T          3420          4578                  1.03                     0.84--1.26   0.77   \<0.001   76%

OR -- odds ratio, CI -- confidence interval, *vs.* -- versus.
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